Malgorzata Pupek

Dr. Malgorzata Pupek


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
Verified
Journal Article
Closed access
EKEwa Karolewska
Ewa Karolewska
TKTomasz Konopka
Tomasz Konopka
MPMalgorzata Pupek
Malgorzata Pupek
ACAlicja Chybicka
Alicja Chybicka
MMMagdalena Mendak
Magdalena Mendak

1 June 2013 in Clinical Biochemistry
Verified
Journal Article
Closed access
ALAnna Lemańska-Perek
Anna Lemańska-Perek
MPMalgorzata Pupek
Malgorzata Pupek
BPBożena Polańska
Bożena Polańska
JLJerzy Leszek
Jerzy Leszek
IKIwona Kątnik-Prastowska
Iwona Kątnik-Prastowska

29 March 2016 in Inflammation
Verified
Journal Article
Open access
PDF file
ALAnna Lemańska-Perek
Anna Lemańska-Perek
DKDorota Krzyżanowska-Gołąb
Dorota Krzyżanowska-Gołąb
MPMalgorzata Pupek
Malgorzata Pupek
PKPiotr Klimeczek
Piotr Klimeczek
WWWojciech Witkiewicz
Wojciech Witkiewicz
IKIwona Kątnik-Prastowska
Iwona Kątnik-Prastowska
Atherosclerosis, a chronic vascular disease, leads to molecular events bound with interplaying processes of inflammation and coagulation. In the present study, fibronectin (FN), FN containing extra domain A (EDA-FN), frequency of occurrence, and relative amounts of soluble plasma FN-fibrin complexes were analyzed in 80 plasma samples of patients suspected of coronary artery disease based on clinical evaluation and changes in arteries found by computed tomographic coronary angiography. The study showed that in the plasma of the patients’ group with high risk of coronary artery disease EDA-FN concentration was significantly higher (3.5 ± 2.5 mg/L; P < 0.025) and the molecular FN-fibrin complexes of 1000 kDa and higher occurred more often than in the groups of patients with mild risk of coronary artery disease and the normal age-matched. The increased level of EDA-FN and occurrence of FN-fibrin complexes could have a potential diagnostic value in the diagnosis and management of patients with coronary artery disease.

25 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Katarzyna Kilis-PstrusinskaKatarzyna Kilis-Pstrusinska
Katarzyna Kilis-Pstrusinska
KAKatarzyna Akutko
Katarzyna Akutko
JBJoanna Barbara Braksator
Joanna Barbara Braksator
ADAnna Dancewicz
Anna Dancewicz
PGPatrycja Grosman-Dziewiszek
Patrycja Grosman-Dziewiszek
EJEwa Jankowska
Ewa Jankowska
The disease caused by coronavirus SARS-CoV-2 (COVID-19) can affect almost all organs of the human body, including kidneys. We conducted a one-center study to comprehensively analyze the effects of kidney involvement on the course and outcomes in patients hospitalized with COVID-19, depending on the estimated glomerular filtration rate (eGFR) at admission. Out of the 1958 patients, 1342 (68.54%) had eGFR ≥ 60 mL/min/1.73 m2 (group A) and 616 (31.46%) had eGFR < 60 mL/min/1.73 m2 (group B). Group B was additionally divided into subgroups B1, B2, and B3 based on eGFR. We found that mortality rates during hospitalization, as well as after 90 and 180 days, were much higher in group B than group A. The highest mortality was observed in the B2 subgroup with eGFR of 15–29. The mortality of B patients was associated with comorbidities, respiratory dysfunction, immunological impairment, and more frequent development of AKI. AKI had a negative impact on patients’ survival, regardless of the initial renal function. At discharge, 7.4% of patients had serum creatinine levels 30% higher, or more, as compared to admission. The disease course and outcomes in COVID-19 patients are associated with baseline eGFR; however, AKI during hospitalization is a more significant predictor of poor prognosis regardless of the initial renal function.

1 May 2016 in Experimental Gerontology
Verified
Journal Article
Closed access
MPMalgorzata Pupek
Malgorzata Pupek
RPRobert Pawłowicz
Robert Pawłowicz
KLKarolina Lindner-Pawłowicz
Karolina Lindner-Pawłowicz
DKDorota Krzyżanowska-Gołąb
Dorota Krzyżanowska-Gołąb
ALAnna Lemańska-Perek
Anna Lemańska-Perek
IKIwona Kątnik-Prastowska
Iwona Kątnik-Prastowska

31 May 2009 in Clinical Biochemistry
Verified
Journal Article
Closed access
MPMalgorzata Pupek
Malgorzata Pupek
DKDorota Krzyżanowska-Gołąb
Dorota Krzyżanowska-Gołąb
TDTomasz Dyła
Tomasz Dyła
ALAnna Lemańska-Perek
Anna Lemańska-Perek
RJRenata Jankowska
Renata Jankowska
IKIwona Kątnik-Prastowska
Iwona Kątnik-Prastowska